The orphan nuclear receptor NURR1 belongs to the NR4A subfamily of transcription factors which are emerging as important mediators of cytokine and growth factor signaling. The transcriptional function of these ligandindependent and constitutively active receptors is controlled at the level of expression and nuclear localization. This study examines the expression of NURR1 in psoriasis and biological effects on this receptor following inhibition of tumor necrosis factor-a (TNF-a) signaling. We report increased expression of NURR1 mRNA and protein in involved psoriasis skin compared with uninvolved and normal skin, which correlates significantly (P ¼ 0.0055) with clinical measures of the psoriasis area and severity index. Enhanced NURR1 expression localizes to both nucleus and cytoplasm of cells of involved epidermis, blood vessels, and inflammatory infiltrates, in contrast to predominant cytoplasmic distribution in uninvolved and normal skin. Endogenous NURR1 levels are rapidly and selectively increased in response to proinflammatory agonists and growth factors in normal dermal endothelial cells. Following TNF-a inhibition with infliximab or etanercept, NURR1 mRNA and protein levels in involved skin are significantly decreased and cytoplasmic distribution is restored. These findings establish the aberrant expression and distribution of NURR1 in psoriasis and suggest that clinical benefits of TNF-a inhibition may be mediated through altered NURR1 activity.
INTRODUCTION
Psoriasis is a chronic, inflammatory autoimmune dermatosis that affects 2% of the world population, and is associated with significant morbidity and negative impact on quality of life (Sampogna et al., 2004) . It is characterized by accumulation of erythematous, scaly plaques with characteristic histological changes of epidermal hyperplasia, inflammatory cell infiltrate, and increased vascularity. Approximately 15% of patients develop inflammatory seronegative arthritis, psoriatic arthritis (PsA) (Krueger and Bowcock, 2005) .
The etiology of psoriasis is multifactorial and linked with multiple genetic and environmental factors. There is evidence for both acquired and innate immune dysregulation, with a complex interplay between abnormally activated T-helper lymphocytes, keratinocytes, and the dermal vascular endothelium (Kirby and Griffiths, 2002) . Increased production and release of cytokines and growth factors by activated T lymphocytes triggers basal stem cell keratinocyte proliferation, abnormal terminal differentiation, and resistance to apoptotic signals (Bata-Csorgo et al., 1995; Wrone-Smith et al., 1997) . These inflammatory mediators also support vascular changes and promote angiogenesis, which is a prominent and early event in psoriasis (Brooks et al., 1994; Paleolog et al., 1998; Leong et al., 2005) .
Therapeutic studies of tumor necrosis factor-a (TNF-a) inhibition confirm that this cytokine occupies a prominent place in the hierarchy of signaling molecules and plays a key role in amplifying inflammatory processes associated with psoriasis and PsA . Selective TNF-a inhibitors, including etanercept and infliximab, demonstrate a high degree of clinical benefit in both skin and joint disease (Gottlieb et al., 2005) . TNF-a inhibition significantly reduces cellular infiltration and vessel number with normalization of keratinocyte differentiation in the skin (Lizzul et al., 2005; Markham et al., 2006b) .
Putative roles for primary keratinocyte defects in psoriasis include the corneodesmosin gene (Capon et al., 2004) and abnormal expression of amphiregulin (Chung et al., 2005) and telomerase (Jurisic et al., 2007) by keratinocytes. Neurogenic pathways may also be important in psoriasis.
Several reports document absence of skin and joint disease in areas of sensory denervation and various neuropeptides including corticotropin-releasing hormone (CRH) are increased in psoriasis involved skin (Veale et al., 1993; O'Kane et al., 2006; Saraceno et al., 2006) . Psychological stress significantly affects disease expression and treatment responses (Fortune et al., 2003) , with some patients demonstrating abnormal hypothalamic-pituitary-adrenal axis responses to acute psychological stress. The role of this ''brain-skin axis'' in psoriasis is incompletely understood.
The NR4A subgroup of orphan nuclear receptors (NURR1, NUR77, and NOR-1) belong to the superfamily of ligandinducible transcription factors, which include receptors for steroid hormones, retinoids, and vitamin D (Mangelsdorf et al., 1995) . Transcripts for the NR4A subgroup are constitutively expressed in the central nervous system and play an important role in the coordinate neuroendocrine regulation of the activity of the hypothalamic-pituitary-adrenal axis, including negative feedback inhibition by glucocorticoids (Murphy and Conneely, 1997) . In the pituitary, NURR1 and NUR77 mediate the transcriptional effects of CRH to regulate the gene expression of POMC, the precursor of ACTH. Of note, NURR1 also contributes to the proinflammatory actions of peripheral CRH signaling in human inflammatory joint disease including rheumatoid and PsA (Murphy et al., 2001) .
As ligand-independent nuclear receptors, the activity of NR4A transcription factors is tightly controlled at the level of protein expression and nuclear accumulation (Maxwell and Muscat, 2006) , as well as post-translational modification including phosphorylation (Wingate and Arthur, 2006) . NR4A receptors can interact with other transcription factors including the retinoic acid receptor and co-regulatory proteins to modulate gene expression (Zetterstrom et al., 1996; Wansa and Muscat, 2005; Maxwell and Muscat, 2006) . Unlike most nuclear receptors, however, these proteins are products of immediate early genes whose expression can be differentially induced in response to a variety of signals (Pei et al., 2005; Wansa and Muscat, 2005) . Members of the NR4A subfamily are both necessary and sufficient to regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in vitro and in vivo (Liu et al., 2003; Zeng et al., 2006) . The NR4A receptors contribute to cellular transformation and promote tumor growth by enhancing cell proliferation and mediating TNF-adependent cell survival pathways (Suzuki et al., 2003; Li et al., 2006) .
In chronic inflammatory diseases including arthritis and atherosclerosis, the NR4A receptors are emerging as key regulators of cytokine and growth factor action (McEvoy et al., 2002b; Bonta et al., 2006) . In human synoviocyte cells, transcriptional activation of the NURR1 gene by TNF-a involves NF-kB signaling pathways (McEvoy et al., 2002b) . Elevated levels of NURR1 in synoviocyte cells promote increased expression of IL-8, amphiregulin, and Kit ligand, which may act to promote cell recruitment, proliferation, and survival in the inflamed joint (Davies et al., 2005) . Significantly, recent in vivo studies establish NURR1 as a molecular target of methotrexate action in the treatment of PsA (Ralph et al., 2005) .
We report for the first time increased NURR1 expression and nuclear localization in psoriasis skin, and evidence implicating NURR1 in abnormal keratinocyte proliferation in psoriasis. Our in vitro studies support a role for TNF-a in modulating NURR1 levels and cellular localization in psoriasis, while the pathological importance of this nuclear receptor was confirmed by establishing that TNF-a inhibition can alter the transcriptional regulatory capacity of NURR1 in vivo.
RESULTS
NURR1 expression is increased in psoriatic involved and uninvolved skin compared with normal skin
The expression and localization of NURR1 protein in psoriatic involved and uninvolved skin and normal controls was determined using immunohistochemical analysis. In all involved psoriasis skin samples, abundant staining was seen in the epidermis, dermal blood vessels, and inflammatory infiltrate in and around vessels. Uninvolved and normal skin showed a similar distribution of expression; however NURR1 immunostaining was consistently weaker (Figure 1a-c) . Higher-power views demonstrated that NURR1 expression localized to both nuclear and cytoplasmic compartments in involved skin in contrast to a predominantly cytoplasmic pattern of expression in uninvolved and normal skin. In clinically involved skin, nuclear staining was particularly marked in basal epidermal keratinocytes and scattered collections of suprabasal keratinocytes (Figure 1a and b) , papillary loop vessels (Figure 1b) , and dermal blood vessels ( Figure 1c ). In contrast, vascular staining in uninvolved and normal skin was mainly cytoplasmic (Figure 1c ). The specificity of NURR1 staining was confirmed by absence of staining found on serial tissue sections treated with NURR1 antibody that had been preincubated with an excess of specific antigen (blocking peptide) (Figure 1d ). Immunostaining with isotype-matched nonimmune IgG also yielded negative findings in all skin tissue examined (results not shown).
NURR1 mRNA expression was assessed in involved (n ¼ 12), uninvolved (n ¼ 10) and normal skin samples (n ¼ 4) using reverse transcriptase PCR (RT-PCR). Consistent with the results of the immunohistochemical analysis, NURR1 mRNA levels were higher and more widely distributed in involved and uninvolved psoriasis skin compared with normal skin. While the difference in NURR1 mRNA levels between involved and uninvolved skin ( Figure  1e ) was not statistically significant (P ¼ 0.1537, Student's unpaired t-test), NURR1 mRNA was significantly elevated in involved skin compared with normal controls. (P ¼ 0.0165, Student's unpaired t-test). NURR1 mRNA levels in clinically involved skin correlated significantly with psoriasis area and severity index (PASI) (Spearman r ¼ 0.5961, P ¼ 0.0055).
(n ¼ 3) skin, using double labeling indirect immunofluorescence techniques. Two-color immunofluorescence staining for NURR1 and Ki 67 was performed. Ki 67 antigen is a cellcycle-related nuclear protein, expressed by proliferating cells in all phases of the active cell cycle (G1, S, G2, and M phases) and is absent in resting (G0) cells. It is commonly used as a marker of proliferating keratinocytes in psoriasis, where it is expressed in both basal and suprabasal epidermal layers in contrast to normal skin, where expression is restricted to the basal layer. In all samples analyzed, dual staining demonstrated that the majority of Ki 67-positive cells in the basal and suprabasal layers of involved epidermis also expressed NURR1 in a nuclear distribution. This was in marked contrast to uninvolved and normal epidermis, where nuclear colocalization was almost absent (Figure 2 ), confirming that the abnormal proliferation of keratinocytes in psoriasis is associated with nuclear accumulation of NURR1 protein. Pro-inflammatory mediators, including TNF-a, promote increased NURR1 expression and nuclear localization in primary human dermal microvascular endothelium
To elucidate the molecular signals leading to aberrant NURR1 expression in psoriatic skin, we examined the ability of inflammatory cytokines and growth factors to regulate endogenous NURR1 levels in normal primary dermal microvascular endothelial cells (HMVECs). The effects of proinflammatory agonists on NURR1 mRNA were assessed using Northern blot analysis. Consistent with NURR1 immunostaining in the vasculature in normal skin, basal NURR1 mRNA and protein levels in dermal HMVECs were low (Figure 3a -c). Characteristic of immediate early response genes, induction of NURR1 transcription by proinflammatory agonists exhibited a rapid turnover, with maximal NURR1 mRNA levels peaking at 1 hour ( Figure 3a and b) and returning to basal levels within 3 hours (results not shown). Effects on NURR1 mRNA levels following treatment of dermal HMVECs with TNF-a (3.7-fold), IL-1b (3.7-fold), or prostaglandin E 2 (PGE 2 ) (2.4-fold) were comparable and coadministration of these mediators augmented the effects on NURR1 transcription additively (10.2-fold) ( Figure 3a ) The magnitude of this additive response was comparable to the effects of forskolin (FOR), an established activator of protein kinase pathways shown previously to induce NURR1 expression in many different cell types. Stimulation of dermal HMVECs with the growth factors basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), or transforming growth factor-b resulted in the selective induction of NURR1 mRNA by bFGF (4.6-fold). Interestingly, despite lack of induction by transforming growth factor-b or PDGF, synergistic effects on NURR1 mRNA levels were observed when all three growth factors were added simultaneously (18.3-fold) ( Figure 3b ). Immunofluorescence studies of NURR1 expression in HMVECs confirmed that treatment with cytokines, PGE 2 , or forskolin also induced a rapid and marked increase in endogenous NURR1 protein ( Figure 3c ). Importantly, NURR1 immunostaining in treated cells was enhanced and predominantly nuclear compared with the cytoplasmic localization in untreated cells. Immunofluorescence analysis with nonimmune IgG showed an absence of staining ( Figure 3c ).
Anti-TNF-a treatment reduces nuclear NURR1 expression in psoriatic keratinocytes and blood vessels in vivo
The demonstration that psoriatic skin showed increased levels of NURR1 compared to normal skin and the ability of proinflammatory mediators, including TNF-a, to modulate NURR1 expression and localization in dermal cells in vitro (Figures 1 and 3 ), prompted us to explore the effects of anti-TNF-a treatment on NURR1 expression in vivo. NURR1 expression and cellular distribution were assessed using immunohistochemical analysis of involved psoriasis skin at baseline and at week 12 of etanercept treatment ( Figure 4 , n ¼ 5). All patients had active psoriasis at baseline assessment, with a mean PASI ¼ 3.88. At baseline biopsy, all patient skin (involved and uninvolved) demonstrated histological features of tissue inflammation. Microscopic analysis of involved psoriatic skin confirmed increased epidermal thickness, dermal inflammatory cell infiltrate, and extensive dermal vascularization ( Figure 4a ). Consistent with previous reports on the immunomodulatory effects of etanercept treatment in psoriatic skin disease (Gottlieb et al., 2005) , all patient tissue demonstrated significant reduction in epidermal Before treatment, NURR1 immunostaining was extensive in all tissue samples (n ¼ 5), with abundant nuclear staining observed in the epidermis, dermal blood vessels, and inflammatory infiltrate of involved skin (Figure 4a and b) . Treatment effects on involved skin included overall reduction in the intensity of NURR1 staining, with a marked decrease in nuclear expression in basal keratinocytes (Figure 4c and d) , papillary loop vessels (Figure 4d ), dermal vessel endothelium (Figure 4e) , and inflammatory cells in and around dermal vessels (Figure 4f ). Importantly, most of the NURR1 staining that remained during treatment was predominantly cytoplasmic and comparable to the levels and localization of NURR1 seen in uninvolved or normal skin (Figure 1) .
To verify that the consistent changes in NURR1 protein levels following etanercept treatment (Figure 4a -f) correlated with changes in NURR1 transcription, total RNA was extracted from baseline involved skin (n ¼ 5), baseline uninvolved skin (n ¼ 5), and involved skin at week 12 post etanercept (n ¼ 5), and assessed using RT-PCR. Consistent with the results of our previous analysis (Figure 1e ), NURR1 mRNA levels were elevated in involved skin samples and showed a wide distribution (Figure 5g ). Following treatment, NURR1 mRNA levels in involved skin were reduced and statistical analysis was performed to compare baseline involved skin with baseline uninvolved and post-treatment skin. NURR1 mRNA levels were significantly (P ¼ 0.043) reduced post treatment compared with baseline involved skin ( Figure 5g ). Importantly, etanercept treatment effectively reduced NURR1 mRNA to equivalent levels of NURR1 expressed in uninvolved skin.
Nuclear NURR1 expression is reduced following treatment with anti-TNF-a agents and PUVA
We next assessed the in vivo effects on NURR1 expression using infliximab treatment, an alternative anti-TNF-a agent, and compared the effects of this biologic to etanercept treatment and also to a well established and efficacious nonbiologic treatment, psoralen-ultraviolet A (PUVA). Involved and uninvolved psoriasis skin at baseline and involved skin at week 12 of infliximab (n ¼ 6) or etanercept (n ¼ 5), or week 20 of PUVA (n ¼ 2) treatment, was subjected to immunohistochemical analysis. The majority of patients assessed had a significant clinical response to treatment. There was a broad range of values for PASI pretreatment (mean ¼ 8.2, range 1.5-21.9), with mean PASI post-treatment of 3.6 (range 0-7.8).
Comparable changes in NURR1 expression and cellular distribution were seen following etanercept, infliximab, and PUVA treatments (Figure 5a) . We subsequently performed quantitative analysis of NURR1 nuclear staining in all patient tissue before and following each treatment. Since etanercept's effects on NURR1 expression included reduction and a clearing of nuclear localization in discrete areas of the epidermis, dermis, and blood vessels (Figure 5 ), we performed a separate and detailed quantification for each of these areas following different treatments (Figure 5d ). The percentage of cells positive for NURR1 nuclear staining in clinically involved skin was significantly reduced (Po0.0001) post treatment to levels comparable to those in uninvolved and normal skin (Figure 5d ). Equivalent changes were seen in all tissue areas assessed, including suprabasal and basal epidermis, papillary loop vessels, dermal vessels, dermal fibroblasts, and perivascular inflammatory cells (Figure 5d ). Of note, most NURR1 immunostaining that remained during treatment was predominantly cytoplasmic and was comparable to the NURR1 staining observed in uninvolved and normal skin tissue (Figure 1 ).
DISCUSSION
In this study, we have, for the first time, characterized the expression of the orphan nuclear receptor NURR1 in psoriasis, demonstrating elevated levels in involved skin compared to uninvolved and normal skin. In contrast to clinically involved skin, our analysis of uninvolved and normal skin revealed reduced NURR1 expression at both gene and protein level, with primarily cytoplasmic protein distribution observed in epidermis and dermal vessels. In particular, the basal epidermal layer of normal skin showed almost complete absence of nuclear expression, suggesting nontranscriptional functions for NURR1. Further in vivo studies demonstrated modulation of NURR1 expression and cellular location following successful treatment of psoriasis with anti-TNF-a agents. Since NURR1 is a known downstream target of TNF-a (McEvoy et al., 2002b) , this nuclear receptor may represent a novel therapeutic target with perhaps less side effects than current anti-TNF-a agents. The NR4A group of transcription factors have recently been shown to play key roles in regulating cell growth and transformation, apoptosis, angiogenesis, and inflammation (Li et al., 2006; Maxwell and Muscat, 2006) . These receptors are also implicated in diabetes and atherosclerosis via roles in lipid and glucose metabolism (Bonta et al., 2006; Pei et al., 2006b) . Thus, characterization of their role in psoriasis may contribute to a further understanding of the pathogenesis of psoriasis as well as recently discovered associations between psoriasis and other systemic inflammatory diseases such as coronary vascular disease and diabetes Sommer et al., 2006) .
Our observation of diffuse epidermal NURR1 expression, with enhanced nuclear localization in basal and focal suprabasal layers areas that colocalized with Ki 67, suggests that in addition to being transcriptionally active in these cells, NURR1 may also be involved in the abnormal keratinocyte proliferation, which is a key feature in psoriasis. This could occur via upregulation of amphiregulin expression, an autocrine growth factor for keratinocytes, which induces epidermal hyperplasia, which is increased in psoriasis lesional skin, overexpressed in a mouse model of psoriasis, and associated with synovitis (Cook et al., 2004) . Amphiregulin has recently been described as a target gene modulated by NURR1 transcriptional activity in human synoviocyte cells (Davies et al., 2005) . Additional mechanisms might involve anti-apoptosis effects, since Nur77, another NR4A group member, has both pro-and antiapoptotic functions depending on nuclear or cytoplasmic localization (Li et al., 2006) . So far, only antiapoptotic properties have been demonstrated for NURR1 (Li et al., 2006) . Interestingly, differential nuclear and cytoplasmic distribution in psoriasis has recently been shown for another antiapoptosis protein, survivin, whose nuclear translocation is thought to be an important regulatory mechanism controlling cell proliferation (Markham et al., 2006a) . A further role for NURR1 in cell transformation is supported by the fact that 
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NURR1 upregulation is a feature of tumorigenicity in several cancer cell lines (Ke et al., 2004; Li et al., 2006) and PGE 2 -mediated protection from apoptosis in colorectal cancer depends on NURR1 signaling via CREB (Holla et al., 2006) . NURR1 expression in dermal vessels of involved skin may reflect involvement in angiogenesis, a key early feature of psoriasis that involves upregulation of VEGF and its receptors, endothelial cell proliferation and survival (Markham et al., 2006b) . Transcriptional regulation of NURR1 gene by VEGF has been reported recently (Liu et al., 2003) , while NURR1 can regulate neurophilin, a VEGF receptor expressed in the central nervous system (Hermanson et al., 2006) . Vascular NURR1 expression in psoriasis might also play a role in survival of newly formed vessels via antiapoptotic mechanisms. The role of NURR1 expression by cells of the inflammatory infiltrate in and around dermal vessels (Figure 4 ) is less clear, although a similar finding has been reported in inflamed PsA synovium, where NURR1 expressing cells include macrophage cells of the synovial lining layer and subsynovial regions (Murphy et al., 2001; McEvoy et al., 2002a) .
Certain potential downstream targets of NURR1 are also known to be overexpressed in psoriasis skin, notably at similar locations to those of NURR1. These include IL-8, a central cytokine involved in neutrophil trafficking and expressed in basal and suprabasal keratinocytes (Nickoloff et al., 1991; Ackermann et al., 1999; Jiang et al., 2001) ; VEGF, expressed by keratinocytes and dermal vessels and involved in angiogenesis in psoriasis (Markham et al., 2006b) and NF-kB (Johansen et al., 2005) .
The in vitro effects of proinflammatory cytokines and growth factors on endogenous NURR1 expression in primary dermal endothelial cells are consistent with the pattern of NURR1 expression in psoriasis skin. Basal levels of NURR1 mRNA and protein were low in unstimulated endothelial cells, whereas stimulation with mediators including TNF-a and IL-1b resulted in elevated mRNA and protein levels with predominant nuclear localization. Activation of NURR1 transcription by TNF-a and IL-1b in human synoviocyte cells has previously been shown to involve the p50 and p65 subunits of NF-kB, which is known to regulate the expression of proinflammatory and prosurvival genes (McEvoy et al., 2002b; Pei et al., 2006a) . PGE 2 is a major cylooxygenase-2 product that has been shown to mediate VEGF-induced angiogenesis in primary endothelial cells (Hernandez et al., 2001) . In this study PGE 2 induces NURR1 expression and nuclear localization in primary endothelial cells, suggesting a possible role for NURR1 in modulating prosurvival and proliferative pathways, which could be relevant in the maintenance of newly formed vessels in psoriasis. PGE 2 signals through increased concentrations of intracellular cAMP and altered protein kinase A activity (McEvoy et al., 2004) . The development of novel inhibitors with cellular potency and high protein kinase A selectivity act as effective inhibitors of VEGF-induced endothelial cell growth (Kuo et al., 2005) . Activation of cAMP/PKA/CREB signaling plays a central role in the regulation of cell proliferation associated with synovitis (Wakisaka et al., 1998) , and negative modulators of cAMP/ PKA/CREB signaling have been shown to inhibit IL-6 and IL-8 production and cell hyperproliferation (Takeba et al., 2000) . The rapid induction of NURR1 in endothelial cells following treatment with growth factors including PDGF, may be significant in the context of a recent study describing a role for NR4A receptors in the regulation of PDGF-induced proliferation of vascular smooth muscle (Nomiyama et al., 2006) .
The in vivo effects of treatment with TNF-a inhibitors include a reduction in NURR1 levels and reveal that NURR1 cellular localization is restored to that observed in uninvolved or normal skin. This suggests that the marked clinical effects of anti-TNF-a agents in skin may occur via their effects on NURR1 transcriptional activity. Reductions in nuclear NURR1 protein expression by anti-TNF-a medications were similar to changes in skin treated with PUVA, which is also known to promote apoptosis of TNF-a-producing cells (Coven et al., 1999) . Our group has previously shown that the effects of methotrexate in inflamed psoriatic synovium include a significant (P ¼ 0.001) reduction in NURR1 protein levels and an absence of nuclear expression in lining layer cells, endothelium, and inflammatory cell infiltrate (Ralph et al., 2005) . Further studies in skin incorporating earlier time points, larger treatment cohorts, and a range of different treatments, would determine whether changes in NURR1 are primarily due to direct effects of a therapeutic agent on mediators upstream of NURR1 (such as TNF-a, adenosine), or simply secondary to clinical improvement in psoriasis.
NURR1 and other NR4A group members have an important role in central hypothalamic-pituitary-adrenal axis regulation including transcriptional effects on CRH, POMC, and enzymes that control cortisol production. NURR1 expression in skin suggests similar pathways may operate locally since the skin is both a target and source of steroid hormones (Slominski et al., 2005) and recent reports confirm a local cutaneous hypothalamic-pituitary-adrenal-like system which responds to local stressors and may form part of the increasingly recognized ''brain-skin pathway'' (Slominski et al., 2006b) . Involvement of the NR4A group in peripheral regulation of steroidogenesis has been reported in the testis (Hong et al., 2004) where NF-kB activation by TNF-a has been shown to inhibit transactivation by Nur77 resulting in suppression of genes required for steroidogenesis. Peripheral CRH has proinflammatory actions in the skin (Slominski et al., 2006a) , is also upregulated in inflamed synovium and CRH receptor-mediated responses have been shown to signal through NURR1 (Murphy et al., 2001) . Increased CRH expression and colocalization of CRH receptors in the same cells that express NURR1 in psoriasis skin (unpublished observations) suggests that CRH, via NURR1 signaling, may be involved in psoriasis pathogenesis.
Our work, and that of others, supports a role for NURR1 in the regulation of pathways controlling cell proliferation, apoptosis, and angiogenesis, key events that promote chronic inflammation. It is however unclear whether these transcription factors are primarily proinflammatory or whether in situations of physiological conditions or early/ acute inflammation, they may also have a protective role. There is for example compelling evidence regarding the role of NR4A receptors in both pro-resolution and protective pathways, in the pathogenesis of atherosclerosis (Bonta et al., 2006) . This study contributes to evidence for a role for NURR1 in promoting TNF-a-mediated mechanisms of inflammation at local sites such as skin and joint, and may help to explain the association of systemic inflammatory disease such as atherosclerosis Mallbris et al., 2006; Neimann et al., 2006; Wakkee et al., 2007) and metabolic syndrome (Sommer et al., 2006) with severe psoriasis. While anti-TNF-a agents are undoubtedly effective in treating psoriasis and PsA, modulation of NURR1 activity may be a potential alternative downstream target in future psoriasis therapies.
MATERIALS AND METHODS

Patients and biopsies
Patients with moderate to severe chronic plaque psoriasis (n ¼ 10), and some with both psoriasis and psoriatic arthritis (n ¼ 5), were recruited from the dermatology and rheumatology outpatients departments at the Adelaide and Meath Hospital Dublin and the Rheumatology department at St Vincent's University Hospital Dublin, respectively. Ethical approval was obtained from the local Hospital Ethics Committee in accordance with the Declaration of Helsinki Principles. Following informed, written consent, patients underwent clinical assessment and skin biopsy before beginning treatment with etanercept, infliximab, or PUVA. Etanercept (Enbrel s ) was given as a twice weekly 25 mg subcutaneous dose. Infliximab (Remicade s , Centocor, Malvern, PA) was given at a dose of 3-5 mg/kg at weeks 0, 2, and 6. PUVA was given twice weekly according to standard protocols. All patients were followed up through week 20. Clinical evaluations performed at baseline and weeks 12, 16, and 20 included the PASI for skin and the threevariable disease activity score for joints.
Punch biopsies (6 mm) were taken from the leading edge of active plaques and from uninvolved skin at least 5 cm from involved skin. Biopsies were taken from the extensor surface of upper or lower limbs. Pre-and post-treatment biopsies were taken from the same site. Biopsies from four healthy volunteers were used as normal controls. Each biopsy was divided into two parts for RT-PCR and immunohistological analysis; specimens for immunohistological analysis were immersed in Tissue Tek OCT compound (Sakura, Zoeterwoude, The Netherlands) and snap frozen in liquid nitrogen for storage at À801C until required.
Cell culture and stimulation
Primary dermal HMVECs were commercially sourced (BioWhittaker, San Diego, CA) and cultured in EBM2 s -MV media (BioWhittaker) as previously described (Xu et al., 1994) . Cells were grown in T25cm 2 flasks for RNA analysis, or plated onto sterile eight-chambered tissue culture treated glass slides for subsequent immunofluorescence staining. All cells were used between 4 and 6 passages and grown to 80% confluency before stimulation. Cells were grown in serum-free media for 24 hours then left untreated, or treated for 1 hour with vehicle (Ctrl), forskolin (25 mM) (Sigma-Aldrich, Dorset, UK), PGE 2 (1 mM) (Sigma, St Louis, MO), recombinant human IL-1b (10 ng/ml) (Calbiochem, San Diego, CA), TNF-a (10 ng/ml) (Calbiochem, San Diego, CA), transforming growth factor-b (10 nM) (R&D Systems, Oxfordshire, UK), bFGF (10 nM) (R&D Systems), and PDGF (10 nM) (R&D Systems) before Northern blot analysis; or treated for 1 hour with vehicle (Ctrl), forskolin (FOR, 25 mM Sigma-Aldrich), PGE 2 (1 mM) (Sigma), recombinant human IL-1b (10 ng/ml) (Calbiochem,) and TNF-a (10 ng/ml) (Calbiochem), before immunofluorescence analysis.
Immunohistochemistry
Cryostat serial skin sections (7 mm) were cut, mounted on 3-aminopropyltriethoxysilane-coated glass slides, air dried overnight at 371C then wrapped in foil and stored at À801C until required. Sections were fixed in 1% paraformaldehyde for 20 minutes. Endogenous peroxidases were quenched before staining by treatment with 0.5% H 2 O 2 for 5 minutes and nonspecific binding sites blocked by incubation with dilute normal goat serum (Vector Laboratories, Burlingame, CA) for 2 hours. A three-step immunoperoxidase staining technique was employed. Sections were stained with a polyclonal rabbit anti-NURR1 primary antibody (Santa Cruz Biotechnology, Heidelberg, Germany) that recognizes the amino terminus (N20) of human and rat NURR1. The primary antibody was diluted (1/350) in 10% normal goat serum (Vector Laboratories) and incubated with sections overnight at 41C. Biotinylated anti-rabbit secondary antibody was added the following day and sections incubated with the avidin-biotin-peroxidase complex (VECTASTAIN Elite ABC kit; Vector Laboratories). Negative controls included sections stained with isotype-matched nonimmune IgG and primary antibody preabsorbed with excess specific synthetic peptide (blocking peptide; Santa Cruz Biotechnology). Color was developed in a solution containing diaminobenzidine tetrahydrochloride (Sigma) and 0.5% H 2 O 2 in phosphate-buffered saline (pH 7.6). Slides were counterstained with hematoxylin and mounted. Microscopic analysis was performed on randomly coded slides by two blinded assessors. Where differences in scoring occurred, slides were reviewed by both assessors and a consensus score obtained. Randomly selected high-power fields at Â 400 magnification were scored using a six-point scoring system, where 0 o1% positive cells; 1, 1-10%; 2, 11-25%; 3, 26-50%; 4, 51-75%, and 5, 76-100%. A minimum of 10 high-power fields in each section was averaged to give a mean score. For each high-power field, a separate score for percentage positive cells was made for suprabasal epidermis, basal epidermis, papillary loop vessels, dermal blood vessels, and dermal interstitial cells. Percentage cells positive for nuclear NURR1 and for cytoplasmic NURR1 were scored separately. These scoring techniques have been previously validated and reported (Youssef et al., 1998a, b) .
Immunofluorescence studies
Single labeling immunofluorescence. Primary dermal HMVEC were grown on eight-chambered culture slides (BD Biosciences) and maintained in serum-free endothelial growth media-2 microvascular (EGM-2 mv) media for 24 hours before stimulation with cytokines and growth factors as described above. Following stimulation, media was removed and cells washed with ice-cold phosphate-buffered saline, permeated and fixed in 1% paraformaldehyde. Cells were incubated with diluted normal goat serum (Vector Laboratories) for 2 hours then incubated with NURR1 polyclonal antibody (N-20, 200 mg/ml) (Santa Cruz Biotechnology) diluted 1:10 in 10% normal www.jidonline.org 307 M O'Kane et al.
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Modulation by Anti-TNF-a Agents in Psoriasis human serum, for 90 minutes. A biotinylated secondary anti-rabbit antibody (Vector Laboratories) was added for 30 minutes (1:500, Vector Laboratories), followed by incubation with a Cy3 fluorochrome-conjugated anti-biotin mAb (BN-34; 1.2 mg/ml; 1:100, Sigma). Slides were mounted in fluorescent mounting medium (Dako, Carpinteria, CA). Isotype-matched nonimmune IgG and primary antibody preabsorbed with its specific synthetic peptide were used as negative controls. Double labeling immunofluorescence. Cryosections were prepared from involved, uninvolved, and normal skin as in the previous section and sequential dual labeling for NURR1 performed using a NURR1 polyclonal antibody (N-20, 200 mg/ml) (Santa Cruz Biotechnology) diluted 1:10 in 10% normal human serum, for 90 minutes, followed by incubation with a biotinylated secondary anti-rabbit antibody (Vector Laboratories) as above. Following a second blocking step using normal goat serum (Vector laboratories) for 1 hour, a monoclonal Ki 67 antibody (DAKO Cytoformaton, Glostrup, Denmark) was applied for 1 hour. The primary antibodies NURR1 and Ki 67 were detected by application of a Cy3 fluorochrome-conjugated anti-biotin mAb (BN-34; 1.2 mg/ml; 1:100, Sigma) and FITC-conjugated goat anti-mouse antibody respectively, visualized by a Carl Zeiss fluorescent microscope with subsequent image analysis using Axiovision LE Rel 4.6 software. Mounting techniques and negative controls were as above for single labeling immunofluorescence.
RNA preparation and complementary DNA synthesis
Total RNA (tRNA) was isolated from psoriasis skin and normal control skin using TRIzol TM (Invitrogen) . The absorbance at 260 and 280 nm was measured using a spectrophotometer to determine the concentration and quality of RNA. Quality was also assessed by agarose gel electrophoresis. Complementary DNA was synthesized from 1 or 2 mg of tRNA using Moloney murine leukemia virus reverse transcriptase. PCR was performed to amplify specific gene sequences using Platinum Taq and oligonucleotide primers for NURR1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The sense (5 0 -CGA CAT TTC TGC CTT CTC C-3 0 ) and antisense (5 0 -GGT AAA GTG TCC AGG AAA AG-3 0 ) primer pair was used to amplify human NURR1, yielding a 277-bp product. The sense (5 0 -CCA CCC ATG GCA AAT TCC ATG GCA-3 0 ) and antisense (5 0 -TCT AGA CGG CAG GTC AAG TCC ACC-3 0 ) primer pair was used to amplify GAPDH, yielding a 465-bp product. Both primer pairs flanked intron sequences. The conditions for amplification were as follows: an initial denaturation step at 971C for 2 minutes, followed by denaturation at 971C for 30 seconds, primer annealing at 551C for 30 seconds, and extension at 721C for 30 seconds. PCR was performed in 50-ml volumes containing 2 ml of cDNA reaction mixture, 1.25 mM of each dNTP, 100 ng of each primer, and 2 mM MgCl 2. Each sample underwent a 30-cycle amplification for GAPDH and 35 cycles for NURR1. These cycle numbers were chosen following optimization experiments on a range of patient samples, normal control samples, and positive control tissue, which ensured that the reactions had not reached the plateau phase of amplification at these cycle numbers. PCR products were electrophoresed on a 1.5% agarose gel, visualized with ethidium bromide under UV light, and recorded both on film and as jpeg images (ImageMaster VDS, Amersham Biosciences, Buckinghamshire, UK). The band size was compared to a 100-bp DNA ladder. Densitometric analysis of PCR products was performed to obtain semi-quantitative values for NURR1 normalized to GAPDH. Using the Student's unpaired t-test, comparisons were made between involved and uninvolved skin at baseline; involved and normal control skin at baseline; pre-and post-treatment involved skin.
Northern blot analysis
Cell cultures grown in 25-cm 2 tissue culture flasks were maintained in serum-free EBM2-MV media for 24 hours before treatment as described above. Total RNA was isolated from cultured primary dermal HMVEC using the RNeasy minikit (Qiagen, Crawley, West Sussex, UK) and quantified by UV absorption, then 10 mg of total RNA was electrophoresed on a standard Northern gel and transferred to nylon membrane (Bio-Rad, Hercules, CA). NURR1 cDNA, spanning the amino-terminal region to avoid cross-hybridization, and GAPDH cDNA were radiolabeled to a high specific activity using [a-32 P]dCTP, using a random primer labeling system (Promega, Southampton, UK) (Murphy and Conneely, 1997) . Blots were exposed to film at À801C using intensifying screens, and autoradiographic intensity was quantified using an imaging densitometer. Densitometric values provided are representative of at least three separate experiments and are expressed as fold induction over basal levels relative to GAPDH expression.
Statistical analysis
Data analysis was preformed using InStat software (GraphPad). Student's unpaired t-test was used to compare differences between groups, and Spearman's rank correlation was used to assess correlation of NURR1 mRNA levels with PASI.
